ROBERTO RIOS VALLE: Open Payments
NPI 1710528567 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$417 in 20 payments from 13 companies in 2025. Trend: 2023 $365 · 2024 $375 · 2025 $417
Food & beverage: $417
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 4 | $82 |
| Novo Nordisk Inc | 3 | $76 |
| Lilly USA, LLC | 2 | $44 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $33 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Globus Medical, Inc. | 1 | $20 |
| ABBVIE INC. | 1 | $19 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
Products named: AUSTEDO XR, Auvelity, CAPLYTA, MOUNJARO, Ozempic, Rybelsus, UZEDY, Wegovy.
Industry payments across TX — which companies pay providers there.
